Biome Australia Ltd licences, develops, and markets evidence-based, complementary medicines, including nutraceuticals food-based vitamins and weight management products and live biotherapeutics. The firm owns brands namely; Activated Nutrients: a range of completely organic, plant-based, all-in-one nutritional products; Activated Probiotics: a first-of-its-kind range of clinically-backed precision probiotics. The company has one operating segment: researching, developing, manufacturing and distributing innovative evidence-based products linking the gut and human health. Domestically it caters to Australia and In international markets, the Group distributes and markets its Activated Probiotics range in the United Kingdom and New Zealand through independent health practitioners.
相关临床试验
0
0 进行中
药物批准
56
批准总数
监管机构
1
监管机构数
成立时间
1952
暂无试验阶段数据
暂无试验数据
暂无试验数据
- The global urinalysis market is projected to grow from USD 4.88 billion in 2026 to USD 7.16 billion by 2031, at a compound annual growth rate (CAGR) of 8.0%. - The consumables segment held the largest market share at 72.5% in 2025, while pregnancy and fertility tests led test types with a 42.8% share. - North America remains the largest regional market, with Asia Pacific expected to register the fastest growth during the forecast period. - Growth is driven by rising prevalence of urinary tract infections, diabetes, and kidney and liver diseases, alongside increasing adoption of automated and point-of-care testing.
- The global epigenomics market is projected to grow from US$16.9 billion in 2024 to US$69.6 billion by 2034, a 15.2% CAGR. - Oncology dominates applications with a 57.2% share, while DNA methylation leads the technology segment at 48.1% of revenue. - More than 10 epigenetic drugs are approved and over 35 epigenetic therapies are in clinical trials worldwide, signaling expanding therapeutic investment. - North America holds a leading 41.3% market share, with Asia-Pacific forecast to record the fastest growth through 2034.
- Amgen faces antitrust challenges over its alleged use of acquired Roche patent rights to extend Enbrel's market exclusivity until 2029, blocking lower-cost biosimilar competitors. - The Open Markets Institute filed an amicus brief urging the Fourth Circuit to allow the CareFirst v. Amgen lawsuit to proceed, arguing acquisitions of pending patents can constitute illegal monopolization under the Sherman Act. - Sandoz's separate antitrust appeal was dismissed by the Eastern District of Virginia, which found Amgen's patent enforcement protected under Noerr-Pennington doctrine and barred as a compulsory counterclaim. - Former Chief Judge Paul Michel, PhRMA, BIO, and the Washington Legal Foundation filed briefs supporting Amgen, warning that Sandoz's broad antitrust theory would disrupt the U.S. patent system.
- Cancer survival rates have improved from 50% to 70% over five decades, yet patients still face years-long waits for promising therapies to navigate clinical development and regulatory pathways. - Mid-sized biotech companies serve as the critical bridge between university discoveries and patient care, advancing therapies through clinical trials that larger firms may deem too risky. - Policymakers must modernize clinical trial processes, ensure timely coverage and reimbursement after FDA approval, and preserve conditions that sustain long-term biotech investment. - Global competition in biotechnology is intensifying, with China making the sector a strategic national priority, threatening America's longstanding leadership in medical innovation.
- ASBMB's weekly opportunities list features new meetings, awards, scholarships, and events for bioscience professionals, with member offerings prioritized. - Rice University's Future Leaders in Bioengineering Seminar Series invites postdoctoral fellows and senior Ph.D. students to apply by June 30, 2026, with travel and lodging support provided. - The U.S.–Chile Fulbright Antarctic Science Exchange will support approximately five early-career scientists for collaborative Antarctic research on extremophiles and molecular adaptation, with applications due September 15, 2026. - HHMI's Presidential Fellows Program offers a two- to three-year appointment for early-career professionals to work on strategic initiatives at HHMI headquarters in the Washington, D.C., area.
- The FDA has begun discussions for PDUFA VIII reauthorization with a target enactment date of September 2027, emphasizing an "America First" approach to drug approval processes. - Key meetings are scheduled with BIO and PhRMA representatives, involving leaders from FDA's CDER and CBER to discuss funding structures and performance goals. - The negotiations may include measures to streamline approvals for domestically developed drugs and incentivize innovation within U.S.-based pharmaceutical companies. - These discussions will shape future policies impacting drug development timelines, regulatory efficiency, and how new therapies reach patients over the next five-year cycle.
